Dermatologic adverse events associated with afatinib: An oral ErbB family blocker
Journal
Expert Review of Anticancer Therapy
Journal Volume
13
Journal Issue
6
Pages
721-728
Date Issued
2013
Author(s)
Lacouture M.E.
Schadendorf D.
Uttenreuther-Fischer M.
Stammberger U.
O'Brien D.
Hauschild A.
Abstract
Dermatologic adverse events (AEs) are frequently observed in patients receiving EGF receptor (EGFR; also known as ErbB1) tyrosine kinase inhibitor therapy. The impact of these AEs goes beyond cosmesis to the discomfort from itching, pain and secondary infections, all of which may significantly impact on patient well-being, adherence and clinical outcomes. Afatinib is a potent, irreversible, oral, ErbB family blocker, inhibiting EGFR (ErbB1), HER2 (ErbB2) and ErbB4 receptor kinases. It also inhibits transphosphorylation of ErbB3. Similar to EGFR inhibitors, dermatologic AEs have been frequently observed in patients treated with afatinib. Papulopustular (acneiform) rash, pruritus, xerosis, paronychia and alopecia will require patient education and proactive treatment interventions. This article summarizes current data on the dermatologic AEs associated with afatinib treatment across the clinical trial program, and provides strategies for their effective management. ? 2013 2013 Expert Reviews Ltd.
SDGs
Other Subjects
4 aminobutyric acid receptor stimulating agent; afatinib; alclometasone; antibiotic agent; antihistaminic agent; antiinfective agent; capecitabine; clindamycin; desonide; doxycycline; epidermal growth factor receptor; epidermal growth factor receptor 2; epidermal growth factor receptor 3; epidermal growth factor receptor 4; epidermal growth factor receptor kinase inhibitor; erlotinib; erythromycin; fluticasone propionate; gefitinib; lapatinib; metronidazole; minocycline; oxytetracycline; paclitaxel; placebo; silver nitrate; steroid; tacrolimus; triamcinolone acetonide; unindexed drug; acne; alopecia; breast cancer; breast metastasis; bullous dermatitis; diarrhea; drug dose escalation; drug dose reduction; drug efficacy; drug eruption; drug response; drug safety; drug substitution; drug tolerability; drug withdrawal; dry skin; erythema; erythroderma; hair; hand foot syndrome; head and neck squamous cell carcinoma; human; hypertrichosis; lung adenocarcinoma; lung non small cell cancer; macular rash; maculopapular rash; molecularly targeted therapy; monotherapy; mucosa inflammation; overall survival; pain; papular rash; papulopustular rash; paronychia; patient education; pruritus; pustule; pyoderma gangrenosum; quality of life; radiation dermatitis; review; secondary infection; side effect; skin disease; skin exfoliation; skin fissure; solid tumor; vesicular rash; xerosis; Administration, Oral; Alopecia; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Exanthema; Humans; Paronychia; Protein Kinase Inhibitors; Pruritus; Quinazolines; Receptor, Epidermal Growth Factor; Receptor, erbB-2
Type
review